文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

微脉冲激光联合雷珠单抗治疗糖尿病黄斑水肿的疗效:随机对照试验研究方案

The efficacy of micropulse laser combined with ranibizumab in diabetic macular edema treatment: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2022-09-02

本方案为前瞻性随机双盲对照临床试验,比较微脉冲激光联合雷珠单抗与雷珠单抗单药治疗糖尿病黄斑水肿的疗效,随访1年,主要终点为ETDRS视力,次要终点为OCT测量的黄斑中心厚度和注射次数,旨在判断联合治疗是否非劣于单药治疗。

要点

  • 微脉冲激光联合雷珠单抗可能减少眼内注射次数,减轻患者经济与心理负担。
  • 主要终点为ETDRS视力,次要终点为OCT测量的黄斑中心厚度和两组注射次数。
  • 目前微脉冲激光治疗DME的参数和具体方法尚无治疗共识,缺乏联合治疗的临床研究数据参考。

核心结论

  • 本研究旨在判断微脉冲激光联合雷珠单抗治疗DME的疗效是否非劣于雷珠单抗单药治疗。
  • 联合治疗可能减少玻璃体腔抗VEGF注射次数,但微脉冲激光治疗DME的参数和具体方法尚无治疗共识。
  • 研究拟为临床DME治疗提供新方向,并为微脉冲激光在DME治疗中的应用提供现实考量。

研究设计与样本

  • 前瞻性随机双盲对照临床试验,纳入DME患者,随访1年。
  • 比较微脉冲激光联合雷珠单抗组与雷珠单抗单药治疗组。
  • 主要终点为ETDRS视力表测量的视力,次要终点为OCT测量的黄斑中心厚度和两组注射次数。
  • 招募前向患者提供知情同意,说明研究目的和流程。
  • 试验注册号NCT03690947,注册日期2018年10月1日。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出微脉冲激光治疗DME的参数和具体方法尚无治疗共识。
  • 原文指出缺乏微脉冲激光联合抗VEGF治疗在临床实践中的临床研究数据参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: At present, intraocular injection of anti-VEGF (vascular endothelial growth factor) drugs has replaced traditional laser therapy as the first-line treatment for DME (diabetic macular edema). However, ranibizumab, a commonly used anti-VEGF drug, is expensive and requires multiple intraocular injections. It places a heavy economic burden on patients with DME. Micropulse laser is safer than conventional laser and can reduce edema. Combined treatment with anti-VEGF may reduce the number of intraocular injections. This study will compare the efficacy of micropulse laser combined with ranibizumab treatment to ranibizumab monotherapy in the treatment of DME, providing a new regimen for future DME treatment. METHODS: This study is a prospective randomized double-blind controlled clinical trial (RCT) in patients with DME. After 1-year follow-up, visual acuity and macular edema regression will be compared between micropulse laser combined with ranibizumab group and ranibizumab monotherapy group to determine whether the efficacy of micropulse laser combined with ranibizumab treatment was not lower than that of ranibizumab monotherapy in the treatment of DME. Visual acuity measured by the ETDRS chart is the primary outcome measure. The secondary outcome measures are CMT (central macular thickness) measured by OCT (optical coherence tomography) and the number of injections of two groups. Changes in visual acuity and CMT of the two groups will be compared at 12-month follow-up. Before patients are recruited, we provide them with informed consent, in which we explain to them the purpose and process of the study. DISCUSSION: Micropulse laser combined with anti-VEGF drugs in the treatment of DME can reduce the number of intravitreal anti-VEGF injections, not only relieve the pain of the patients, but also ease the economic and psychological burden of patients, bringing great benefits. However, there is no treatment consensus for the parameters and specific methods of micropulse laser treatment for DME. There is a lack of clinical research data reference of micropulse laser combined with anti-VEGF therapy in clinical practice. This study intends to provide a new direction for clinical DME treatment and also provide a realistic consideration for the application of micropulse laser in DME treatment. TRIAL REGISTRATION: ClinicalTrials.gov NCT03690947. Registered on 1 October 2018.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Mi X, Gu X, Yu X, et al. The efficacy of micropulse laser combined with ranibizumab in diabetic macular edema treatment: study protocol for a randomized controlled trial. Trials. 2022. PMID: 36056443. doi:10.1186/s13063-022-06593-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。